A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

Oncogene

Volumn 32, Issue 50, 2013, Pages 5593-5601

  Castoldi, R ^a   Ecker, V ^a   Wiehle, L ^a   Majety, M ^a   Busl Schuller, R ^a   Asmussen, M ^a   Nopora, A ^a   Jucknischke, U ^a   Osl, F ^a   Kobold, S ^b   Scheuer, W ^a   Venturi, M ^a   Klein, C ^c   Niederfellner, G ^a   Sustmann, C ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Roche Glycart AG   (Switzerland)

Author keywords

bispecific antibody; EGF; EGFR; HGF; Met

Indexed keywords

5D5 ANTIBODY; BISPECIFIC ANTIBODY; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MATRIGEL; METHER1 ANTIBODY; ONARTUZUMAB; PANITUMUMAB; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CLINICAL EVALUATION; DRUG BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR GROWTH; UPREGULATION; XENOGRAFT;

EID: 84890551686     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.245     Document Type: Article

References (47)

1. Alexander S, Friedl P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol Med 2012; 18: 13-26.
2. Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 2007; 3: 151.
3. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275: 8806-8811.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
5. Nedergaard MK, Hedegaard CJ, Poulsen HS. Targeting the epidermal growth factor receptor in solid tumor malignancies. BioDrugs 2012; 26: 83-99.
6. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-848.
7. Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
8. Yap TA, Sandhu SK, Alam SM, de Bono JS. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets 2011; 12: 2045-2058.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
10. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
11. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009; 10: 709-717.
12. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10: 281-289.
13. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogeneaddicted gastric cancer cells. Mol Cancer Ther 2008; 7: 3499-3508.
14. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 2010; 9: 121.
15. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008; 105: 692-697.
16. Hammond DE, Hyde R, Kratchmarova I, Beynon RJ, Blagoev B, Clague MJ. Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. J Proteome Res 2010; 9: 2734-2742.
17. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009; 30: 1097-1105.
18. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011; 17: 472-482.
19. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-9487.
20. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011; 17: 4425-4438.
21. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012; 7: 272-280.
22. Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010; 70: 6880-6890.
23. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011; 11: 1655-1662.
24. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16: 677-681.
25. Yang SY, Miah A, Pabari A, Winslet M. Growth Factors and their receptors in cancer metastases. Front Biosci 2011; 16: 531-538.
26. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 2008; 7: 9.
27. Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 2007; 6: 561-570.
28. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M et al. Cellular targets of gefitinib. Cancer Res 2005; 65: 379-382.
29. Naito Y, Shimizu H, Kasama T, Sato J, Tabara H, Okamoto A et al. Cyclin G-associated kinase regulates protein phosphatase 2A by phosphorylation of its B'gamma subunit. Cell Cycle 2012; 11: 604-616.
30. Ungewickell EJ, Hinrichsen L. Endocytosis: clathrin-mediated membrane budding. Curr Opin Cell Biol 2007; 19: 417-425.
31. Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 2013; 32: 3846-3856.
32. Maseki S, Ijichi K, Tanaka H, Fujii M, Hasegawa Y, Ogawa T et al. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br J Cancer 2012; 106: 1196-1204.
33. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
34. Wang S, Basson MD. Protein kinase B/AKT and focal adhesion kinase: Two close signaling partners in cancer. Anticancer Agents Med Chem 2011; 11: 993-1002.
35. Serrels A, Canel M, Brunton VG, Frame MC. Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging. Cell Adh Migr 2011; 5: 360-365.
36. Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A et al. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Cancer Biol Ther 2012; 13: 6.
37. Sugahara K, Matsumoto M, Baba T, Nakamura T, Kawamoto T. Elevation of serum human hepatocyte growth factor (HGF) level in patients with pneumonectomy during a perioperative period. Intensive Care Med 1998; 24: 434-437.
38. Dikmen E, Kara M, Kisa U, Atinkaya C, Han S, Sakinci U. Human hepatocyte growth factor levels in patients undergoing thoracic operations. Eur Respir J 2006; 27: 73-76.
39. Uchiyama A, Morisaki T, Beppu K, Kojima M, Matsunari Y, Nakatsuka A et al. Hepatocyte growth factor and invasion-stimulatory activity are induced in pleural fluid by surgery in lung cancer patients. Br J Cancer 1999; 81: 721-726.
40. Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 2009; 6: 194-200.
41. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3: 273-288.
42. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280: 19665-19672.
43. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279: 2856-2865.
44. Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Gassner C et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012; 526: 206-218.
45. Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 2011; 108: 8194-8199.
46. Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K et al. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 2006; 12: 183-190.
47. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9: 617-621.